Body & Brain | Science News


Support credible science journalism.

Subscribe to Science News today.

News in Brief

Body & Brain

Coffee may limit prostate cancer, plus protecting organ transplants and limiting HIV transmission in this week’s news

3:41pm, May 20, 2011

Drug limits kidney rejection
The anti-leukemia drug alemtuzumab (Campath) can lessen the risk of immune rejection in some people receiving a kidney transplant, a new study finds. But the results, published in the May 19 New England Journal of Medicine, suggest that the drug doesn’t improve prospects for the patients most prone to rejecting a transplant. Researchers at several U.S. medical facilities enrolled 139 such high-risk patients and 335 low-risk patients to get either alemtuzumab or standard drugs after a kidney transplant. Three years later, 85 percent of low-risk recipients getting alemtuzumab and 76 percent of those on standard medication had survived with no rejection. Among the high-risk group, these percentages were 76 and 70, a difference that could be due to chance. —Nathan Seppa


This article is available only to subscribing members. Join the Society today or Log in.

Get Science News headlines by e-mail.

More from Science News